Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Immunologic aspects of scleroderma.

¹Veterans Administration Medical Center, Newington, Connecticut.

Current Opinion in Rheumatology

|December 1, 1991

Summary

This summary is machine-generated.

T-cell activation is evident in scleroderma, with elevated cytokines and soluble T-cell molecules found in patients. Autoantibodies are present but their role in disease and specific antigens remain unclear.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

Arthritis and rheumatism·2004

Same author

Global expression analysis of the fibroblast transcriptional response to TGFbeta.

Clinical and experimental rheumatology·2004

Same author

What's wrong with the scleroderma fibroblast?

Clinical and experimental rheumatology·2004

Same author

The hcKrox gene family regulates multiple extracellular matrix genes.

Matrix biology : journal of the International Society for Matrix Biology·2001

Same author

Raynaud's phenomenon, scleroderma, overlap syndromes, and other fibrosing syndromes.

Current opinion in rheumatology·2000

Same author

Role of apoptosis and transforming growth factor beta1 in fibroblast selection and activation in systemic sclerosis.

Arthritis and rheumatism·2000

Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026

Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026

Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026

Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026

Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026

Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026

See all related articles

Area of Science:

Immunology
Rheumatology
Scleroderma Research

Background:

Growing evidence suggests T-cell activation occurs in vivo during scleroderma.
Studies have identified circulating cytokines and soluble T-cell membrane molecules in scleroderma serum.

Purpose of the Study:

To review the evidence for T-cell activation in scleroderma.
To discuss the role of autoantibodies and their association with disease subsets and prognosis.

Main Methods:

Review of existing studies on T-cell activation markers in scleroderma.
Analysis of autoantibody patterns and their clinical associations.

Main Results:

Elevated levels of soluble interleukin-2 receptor and CD8 were observed.
Autoantibodies to nuclear-associated antigens are polyclonal and antigen-driven.
Absence of autoantibodies predicts no progression from Raynaud's phenomenon to systemic connective tissue disease.

Conclusions:

T-cell activation is a feature of scleroderma, though specific antigens are unidentified.
Autoantibodies are associated with disease subsets and prognosis, particularly in Raynaud's phenomenon.
Further research is needed to elucidate the precise role of autoantibodies in scleroderma pathogenesis.